Lini Pandite
Overview
Explore the profile of Lini Pandite including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
2426
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Johnson M, Hong D, Brana I, Schoffski P, Galvao V, Rangwala F, et al.
Invest New Drugs
. 2025 Mar;
PMID: 40042547
SL-279252 is a bifunctional hexameric fusion protein adjoining the extracellular domains of PD-1 and OX40L via an inert IgG4 derived Fc domain. A Phase 1 dose escalation study was conducted...
2.
Lakhani N, Stewart D, Richardson D, Dockery L, Van Le L, Call J, et al.
J Immunother Cancer
. 2025 Jan;
13(1.
PMID: 39800375
Background: SL-172154 is a hexameric fusion protein adjoining the extracellular domain of SIRPα to the extracellular domain of CD40L via an inert IgG-derived Fc domain. In preclinical studies, a murine...
3.
Sternberg C, Davis I, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al.
J Clin Oncol
. 2023 Apr;
41(11):1957-1964.
PMID: 37018920
Purpose: Pazopanib is an oral angiogenesis inhibitor targeting vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-Kit. This randomized, double-blind, placebo-controlled phase III study evaluated efficacy and safety...
4.
DAngelo S, Melchiori L, Merchant M, Bernstein D, Glod J, Kaplan R, et al.
Cancer Discov
. 2018 Jun;
8(8):944-957.
PMID: 29891538
We evaluated the safety and activity of autologous T cells expressing NY-ESO-1, an affinity-enhanced T-cell receptor (TCR) recognizing an HLA-A2-restricted NY-ESO-1/LAGE1a-derived peptide, in patients with metastatic synovial sarcoma (NY-ESO-1T cells)....
5.
Planchard D, Kim T, Mazieres J, Quoix E, Riely G, Barlesi F, et al.
Lancet Oncol
. 2016 Apr;
17(5):642-50.
PMID: 27080216
Background: Activating BRAF(V600E) (Val600Glu) mutations are found in about 1-2% of lung adenocarcinomas, which might provide an opportunity for targeted treatment in these patients. Dabrafenib is an oral selective inhibitor...
6.
Diaz J, Sternberg C, Mehmud F, Delea T, Latimer N, Pandite L, et al.
Oncology
. 2016 Feb;
90(3):119-26.
PMID: 26901053
Objective: To identify the issues of using overall survival (OS) as a primary endpoint in the presence of crossover and the statistical analyses available to adjust for confounded OS due...
7.
Goldstein D, Rosenberg J, Figlin R, Townsend R, McCann L, Carpenter C, et al.
Eur J Cancer
. 2015 Dec;
53:96-104.
PMID: 26702763
Aim: Pazopanib, an oral antiangiogenic agent, is associated with improved outcomes in patients with metastatic renal cell carcinoma. In this retrospective analysis, we explore hypertension, an on-target adverse event, as...
8.
Powles T, Bracarda S, Chen M, Norry E, Compton N, Heise M, et al.
Eur J Cancer
. 2015 Apr;
51(10):1293-302.
PMID: 25899987
Drug-induced liver chemistry abnormalities, primarily transaminase elevations, are commonly observed in pazopanib-treated patients. This meta-analysis characterises liver chemistry abnormalities associated with pazopanib. Data of pazopanib-treated patients from nine prospective trials...
9.
Choueiri T, Figueroa D, Fay A, Signoretti S, Liu Y, Gagnon R, et al.
Clin Cancer Res
. 2014 Dec;
21(5):1071-7.
PMID: 25538263
Purpose: The interaction of programmed death-1 ligand (PD-L1) with its receptor (PD-1) on T cells inactivates antitumor immune responses. PD-L1 expression has been associated with poor outcomes in renal cell...
10.
Choueiri T, Fay A, Gagnon R, Lin Y, Bahamon B, Brown V, et al.
Clin Cancer Res
. 2013 Jul;
19(18):5218-26.
PMID: 23881929
Purpose: Inactivation of von Hippel-Lindau (VHL) gene in clear-cell renal cell carcinoma (RCC) leads to increased levels of hypoxia-inducible factors (HIF) and overexpression of HIF target genes, such as VEGF...